Ironwood Pharmaceuticals (IRWD) S-3ASR Automatic shelf registration

Exhibit 12.1

STATEMENT REGARDING COMPUTATION OF RATIOS

	Fiscal Years Ended															Nine Months Ended
	December 31, 2013			December 31, 2012			December 31, 2011			December 31, 2010			December 31, 2009			September 30,2014
Loss from continuing operations	$	(272,812	)	$	(72,624	)	$	(64,849	)	$	(59,355	)	$	(60,294	)	$	(151,971	)
Add back: Fixed charges	21,002			59			63			196			318			15,906
Total loss from continuing operations	(251,810		)	(72,565		)	(64,786		)	(59,159		)	(59,976		)	(136,065		)
Fixed charges:
Interest expense	21,002			59			63			196			318			15,906
Ratio of Earnings to Fixed Charges	*			*			*			*			*			*
Deficiency(1)	$	(272,812	)	$	(72,624	)	$	(64,849	)	$	(59,355	)	$	(60,294	)	$	(151,971	)

*Less than one to one coverage

(1)      Losses in each period.  Earnings insufficient to cover fixed charges by the amounts indicated.